Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464951 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1L3MBTL1PARP1PANK3 | |
| SCHEMBL27424678 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1L3MBTL1PARP1PANK3 | |
| Hydrochloric Acid SCHEMBL12539841 | 0.98 | KDM4E (0.45) | KDM4EALDH1A1L3MBTL1PARP1PANK3 | |
| Hydrochloric Acid SCHEMBL29664540 | 0.98 | KDM4E (0.45) | KDM4EALDH1A1L3MBTL1PARP1PANK3 | |
| SCHEMBL26301186 | 0.84 | KDM4E (0.53) | KDM4EALDH1A1L3MBTL1PARP1PANK3 | |
| SCHEMBL2224273 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1L3MBTL1PANK3GPR119 | |
| SCHEMBL24296015 | 0.81 | RET (0.47) | KDM4EALDH1A1L3MBTL1PARP1PANK3 | |
| SCHEMBL9923396 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1L3MBTL1PARP1PANK3 | |
| SCHEMBL22570975 | 0.81 | RET (0.47) | KDM4EALDH1A1L3MBTL1PARP1PANK3 | |
| SCHEMBL1021345 | 0.81 | RET (0.47) | KDM4EALDH1A1L3MBTL1PARP1PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390462-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240217981-A1 | CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217981-A1 | CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4322951-A1 | CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | Pipeline Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | Pipeline Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220332721-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| WO-2022221450-A1 | CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20210161889-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210161889-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-2513088-B1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2015-07-01 | — | — | EP | disclosed |
| EP-2513088-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI (FR) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011080445-A1 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | KDM4E 2921/4885ALDH1A1 1394/4885L3MBTL1 1260/4885 |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | KDM4E 2921/4885ALDH1A1 1394/4885L3MBTL1 1260/4885 |
| US-12390462-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | KDM4E 2921/4885ALDH1A1 1394/4885L3MBTL1 1260/4885 |
| US-20210161889-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | KDM4E 2921/4885ALDH1A1 1394/4885L3MBTL1 1260/4885 |
| US-20220332721-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | KDM4E 2921/4885ALDH1A1 1394/4885L3MBTL1 1260/4885 |
| US-20240217981-A1 | CRYSTALLINE COMPOUND OF MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | KDM4E 3967/4885ALDH1A1 2815/4885L3MBTL1 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.